title: Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice.
abstract: Meta-analyses are useful to increase knowledge and strengthen evidence about antidepressant treatment supplementary to individual studies.
  
  
  
  A pooled analysis of four multicenter, open-label, prospective, non-interventional studies (2009-2013) was performed to provide further evidence about the antidepressant effectiveness and tolerability of agomelatine (25-50 mg/day) in a large number of non-selected German outpatients with major depressive disorder. The main analysis was performed after 12 weeks (n = 9601) and in subpopulations after 24 and 52 weeks by descriptive statistical methods.
  
  
  
  Overall, 60.1% of patients were pretreated with antidepressants. Concomitant psychiatric diseases (71.9%), co-medication with antidepressants (18.9%) and/or psychotropic medication (31.9%) were observed. Depressive symptoms improved according to the Clinical Global Impression (CGI) in 81% after 12 weeks, a response was observed in 78.7% (CGI-I ≤2), and remission in 34.5% of patients (CGI-S = 1 or 2). In subpopulations, response was documented in 79.3% (W24) and 75.9% (W52) and remission in 38.1% (W24) and 47.5% (W52), respectively. Over 12 weeks, adverse drug reactions (ADRs) were reported for 511 patients (5.32%), most frequently headache (0.92%) and nausea (0.75%), and serious adverse drug reactions (sADR) for 18 patients (0.19%). Between W12-W24 and W24-W52, ADRs were reported for 0.49%/0.99% and sADRs for 0.05%/0%, respectively. Overall, 49 patients (0.5%) showed clinically relevant transaminase elevations (AST/ALT >3 times upper normal value), with 19 patients (0.2%) showing preexisting elevations at the study start. One patient (0.03%) developed hepatitis with reversible symptoms after treatment discontinuation. ADR predominantly occurred within the first weeks of treatment. Mean weight and body mass index (BMI) remained unchanged over 24 weeks.
  
  
  
  In this pooled data analysis, 9601 depressed patients of clinical practice were evaluated over 12 weeks and subpopulations were also analyzed over 24 and 52 weeks. Agomelatine effectively reduced depressive symptoms (CGI-response and remission) with good general tolerability.
authors.affiliation: Institute of Psychological Medicine (IPM), Haag, Germany. ipm@ipm-laux.de.
authors.forename: Gerd
authors.initials: G
authors.lastname: Laux
authors.affiliation: Department of Medical Affairs, Servier Deutschland GmbH, Munich, Germany.
authors.forename: Bettina
authors.initials: B
authors.lastname: Barthel
authors.affiliation: Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Social Foundation Bamberg, Teaching Hospital of the University of Erlangen, Erlangen, Germany.
authors.forename: Göran
authors.initials: G
authors.lastname: Hajak
authors.affiliation: Foundation Alsterdorf Hamburg, Heinrich Sengelmann Krankenhaus, Psychiatry, Psychotherapy, Psychosomatic Medicine, Christian Albrechts University Kiel, Bargfeld-Stegen, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Lemke
authors.affiliation: Psychiatric Hospital Werneck Castle, Werneck, Germany.
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Volz
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D012720:Severity of Illness Index; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D000928:Antidepressive Agents; C084711:agomelatine; D009281:Naphthalenes
keywords: Agomelatine; BMI; Dosage; Effectiveness; Liver function; Major depression; Pooled analysis; Tolerability